Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Treatment Resistant Depression

In brief

This study is intended to evaluate the safety and potential efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion versus placebo in patients with Treatment Resistant Depression.

Key facts

Study ID
NCT02675556
Run by
Joshua M Hare
People needed
1
Starts
2017-10-31
Expected to finish
2019-03-26
Last updated by the study team
2019-04-01

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.